BiotechTube

AB-101 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab

Phase 1Active
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Nephritis - WHO Class III

Conditions

Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE

Trial Timeline

Apr 3, 2024 → Aug 1, 2027

NCT ID
NCT06265220

About AB-101 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab

AB-101 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab is a phase 1 stage product being developed by Artiva Biotherapeutics for Lupus Nephritis - WHO Class III. The current trial status is active. This product is registered under clinical trial identifier NCT06265220. Target conditions include Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06265220Phase 1Active

Competing Products

20 competing products in Lupus Nephritis - WHO Class III

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
tacrolimusAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPre-clinical
23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
77
tacrolimusAstellas PharmaApproved
85
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
77
E6742EisaiPhase 1/2
41
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 1
33
LY3471851 + PlaceboEli LillyPhase 2
52

Other Products from Artiva Biotherapeutics

Allogeneic NK CellsPhase 2
44
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2Phase 2
44
AB-201 + Cyclophosphamide + FludarabinePhase 1/2
33
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + BendamustinePhase 1/2
33
GCC2005 + Cyclophosphamide + FludarabinePhase 1
25